EGFR targeted therapy in lung cancer; an evolving story

about

Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

P2860

Q58567008-02D66239-5D65-4643-9E9D-B84A7C408DDD

P2860

EGFR targeted therapy in lung cancer; an evolving story

Item

http://www.wikidata.org/entity/Q42322394

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

EGFR targeted therapy in lung cancer; an evolving story

@en

EGFR targeted therapy in lung cancer; an evolving story

@nl

type

Item

label

EGFR targeted therapy in lung cancer; an evolving story

@en

EGFR targeted therapy in lung cancer; an evolving story

@nl

prefLabel

EGFR targeted therapy in lung cancer; an evolving story

@en

EGFR targeted therapy in lung cancer; an evolving story

@nl

P1476

EGFR targeted therapy in lung cancer; an evolving story

@en

P2093

C Bartholomew

http://www.w3.org/2001/XMLSchema#string

D Yiannakis

http://www.w3.org/2001/XMLSchema#string

L Eastlake

http://www.w3.org/2001/XMLSchema#string

P Dunn

http://www.w3.org/2001/XMLSchema#string

P2860

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Tyrosine kinase inhibitors in lung cancer.

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

The epidermal growth factor receptor pathway: a model for targeted therapy.

P304

137-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1016/J.RMCR.2017.01.016

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28217439

http://www.w3.org/2001/XMLSchema#string

P932

5302182

http://www.w3.org/2001/XMLSchema#string

EGFR targeted therapy in lung cancer; an evolving story

about

P2860

P2860

EGFR targeted therapy in lung cancer; an evolving story

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932